Related MeSH Hierarchy (6)
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Cerebrovascular Disorders » Brain Ischemia » Brain Infarction » Cerebral Infarction
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Cerebrovascular Disorders » Stroke » Brain Infarction » Cerebral Infarction
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Cerebrovascular Disorders » Brain Ischemia » Brain Infarction » Cerebral Infarction
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Cerebrovascular Disorders » Stroke » Brain Infarction » Cerebral Infarction
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Necrosis » Infarction » Brain Infarction » Cerebral Infarction
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Ischemia » Infarction » Brain Infarction » Cerebral Infarction
Description
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction). MeSH
Hierarchy View
Subtype Terms (5)
CADASIL
9 drugs (6 approved, 3 experimental)
Infarction, Anterior Cerebral Artery
3 drugs (1 approved, 2 experimental)
Infarction, Middle Cerebral Artery
16 drugs (8 approved, 8 experimental)
Infarction, Posterior Cerebral Artery
2 experimental drugs
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (19)
Other Experimental Indicated Drugs (5)
Organization Involved with Phase 4 Indications (123)
Beijing Bionovo Medicine Development Co., Ltd.
Boryung Pharmaceutical Company
Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
Chengdu University of Traditional Chinese Medicines
China Academy of Chinese Medical Sciences
Clinical Institute of the Brain, Russia
Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital
Fundação de Amparo à Pesquisa do Estado de São Paulo
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou Baiyunshan Qixing Pharmaceutical Co Ltd
Guangzhou University of Chinese Medicine
Helena Laboratories Point of Care
Huazhong University of Science and Technology
Hubei University of Chinese Medicine
Hunan Academy of Chinese Medicine
Hunan University of Traditional Chinese Medicine
idv Datenanalyse und Versuchsplanung
Jiangmen Wuyi Hospital of Traditional Chinese Medicine
Jiangsu Kanion Pharmaceutical Co., Ltd
Liaoning Hospital of Traditional Chinese Medicine
Liling Hospital of Traditional Chinese Medicine
Myung In Pharmaceutical Company
National Cerebral and Cardiovascular Center
National Cheng Kung University
National Institute of Neurological Disorders and Stroke (NINDS)
Network for Clinical Stroke Trials
People's Liberation Army of China
Shaanxi Provincial People's Hospital
Shaanxi University of Chinese Medicine
Shanghai University of Traditional Chinese Medicine
Shanxi College of Traditional Chinese Medicine
Shin Kong Wu Ho-Su Memorial Hospital
Taipei Veteran General hospital
The Airport Hospital of Shunyi District
The First Hospital of Qiqihar City
The NO.4 People's Hospital of Hengshui
Tianjin University of Traditional Chinese Medicine
Tianshui Hospital of Traditional Chinese Medicine
Wuxi Hospital of Traditional Chinese Medicine
Organization Involved with Phase 3 Indications (72)
Atrium Medisch Centrum, Heerlen
Badalona Hospital Germans Trias i Pujol
Chinese Academy of Medical Sciences
Djavad Mowafaghian Centre for Brain Health
Duta Wacana Christian University
Fundacion Clinic per a la Recerca Biomédica
Hamilton Health Sciences Corporation
Hospital Santa Marcelina, Sao Paulo, Brasil
Indonesia's Neurologists Organization (Perdossi)
Medical University of South Carolina
National Research Council of Thailand
National University of Singapore
Netherlands Organisation for Scientific Research
Neurological Emergencies Treatment Trials Network
Organization Involved with Phase 2 Indications (117)
Andalusian Initiative for Advanced Therapies
Angde Biotech Pharmaceutical Co., Ltd.
Apeloa Pharmaceutical Co. Ltd.
Applied Health Research Centre
Chandler Regional Medical Center at Chandler AZ
City Hospital No 40, Saint Petersburg, Russia
Inner Mongolia International Mongolian Hospital
Kyunghee University Medical Center
Memorial University of Newfoundland
Nanyang Technological University
National Health and Medical Research Council, Australia
Oregon Health and Science University
Sclnow Biotechnology Co., Ltd.
Shijiazhuang Pharma Group (CSPC)
Subei People's Hospital of Jiangsu Province
The Central Hospital of Lishui City
The Florey Institute of Neuroscience & Mental Health Melbourne Brain Centre
The University of Texas Health Science Center, Houston
Thrombolytic Science International
Universidad Autonoma de Madrid
University of Alabama, Birmingham
University of California, Irvine
University of California, San Diego
University of Texas at Houston
Vancouver Island Health Authority
Organization Involved with Phase 1 Indications (17)
Organization Involved with Other Experimental Indications (21)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.